<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02623725</url>
  </required_header>
  <id_info>
    <org_study_id>CYD64</org_study_id>
    <secondary_id>U1111-1161-2855</secondary_id>
    <nct_id>NCT02623725</nct_id>
  </id_info>
  <brief_title>Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule</brief_title>
  <official_title>Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Latin America</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study was to assess and describe the booster effect of a CYD dengue vaccine
      dose administered 4 to 5 years after the completion of a 3-dose vaccination schedule.

      Primary Objective

      - To demonstrate the non-inferiority, in terms of geometric mean of titer ratios (GMTRs), of
      a CYD dengue vaccine booster compared to the third CYD dengue vaccine injection in
      participants from CYD13 - NCT00993447 and CYD30 - NCT01187433 trials (participants from Group
      1 only).

      Secondary Objectives:

        -  If the primary objective of non-inferiority was achieved: To demonstrate the
           superiority, in terms of GMTRs, of a CYD dengue vaccine booster compared to the third
           CYD dengue vaccine injection in participants from CYD13 and CYD30 trials.

        -  To describe the immune responses elicited by a CYD dengue vaccine booster and placebo
           injection in participants who received 3 doses of the CYD dengue vaccine in the CYD13
           and CYD30 trials in all participants.

        -  To describe the neutralizing antibody levels of each dengue serotype post-dose 3 (CYD13
           and CYD30 participants) and immediately prior to booster or placebo injection in all
           participants.

        -  To describe the neutralizing antibody persistence 6 months, 1 year, and 2 years post
           booster or placebo injection in all participants.

        -  To evaluate the safety of booster vaccination with the CYD dengue vaccine in all
           participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy adolescents and adults who received 3 doses of the tetravalent dengue vaccine 4 to 5
      years earlier in previous CYD dengue vaccine trials (CYD13 and CYD30) received either a
      booster dose CYD dengue vaccine or a placebo on Day 0. They were evaluated for safety and
      antibody persistence of the booster injection up to 2 years post-vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 14, 2016</start_date>
  <completion_date type="Actual">October 28, 2018</completion_date>
  <primary_completion_date type="Actual">November 23, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>An observer-blind procedure was followed for the injection of the CYD Dengue Vaccine booster or placebo. Neither the observer Investigator, nor the Sponsor, nor the participant/participants' parent(s)/legally acceptable representative(s) knew which product was administered.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With CYD Dengue Vaccine in CYD64 Compared to Third CYD Dengue Vaccine Received in CYD13/CYD30: CYD Dengue Vaccine Booster Group</measure>
    <time_frame>28 days post-dose 3 in CYD13 or CYD30 and 28 days post-booster injection in CYD64</time_frame>
    <description>Geometric Mean Titers (GMTs) of antibodies against each of the 4 dengue virus serotype (parental strains) were assessed using the plaque reduction neutralization test (PRNT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GMTs of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With CYD Dengue Vaccine in CYD64 Compared to Third CYD Dengue Vaccine Received in CYD13/CYD30: CYD Dengue Vaccine Booster Group</measure>
    <time_frame>28 days post-dose 3 in CYD13 or CYD30 and 28 days post-booster injection in CYD64</time_frame>
    <description>GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) following booster injection were assessed using PRNT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTs of Antibodies Against Each Dengue Virus Serotype Before And Following Booster Injection (Inj.) With Either CYD Dengue Vaccine or Placebo</measure>
    <time_frame>Pre-booster injection (Day 0) and 28 days post-booster injection</time_frame>
    <description>GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) following booster injection were assessed using PRNT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTRs of Antibodies Against Each Dengue Virus Serotype Before and Following Booster Injection With Either CYD Dengue Vaccine or Placebo</measure>
    <time_frame>Pre-booster injection (Day 0) and 28 days post-booster injection</time_frame>
    <description>GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) following booster injection were assessed using PRNT. GMTRs were calculated as the ratio of GMTs post-booster injection and pre-booster injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Before and Following Booster Injection With Either CYD Dengue Vaccine or Placebo</measure>
    <time_frame>Pre-booster injection (Day 0) and 28 days post-booster injection</time_frame>
    <description>Seropositivity against each dengue virus serotype were measured using dengue PRNT. Seropositive participants were defined as the participants with neutralizing antibody titers greater than or equal to (&gt;=)10 (1/dilution).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion Against Each Dengue Virus Serotype Following Booster Injection With Either CYD Dengue Vaccine or Placebo</measure>
    <time_frame>28 days post-booster injection</time_frame>
    <description>Seroconversion for each serotype was defined as the percentage of participants with either a pre-booster titer &lt;10 (1/dilution) and a post-booster titer &gt;=40 (1/dilution), or a pre-booster titer &gt;=10 (1/dilution) and a &gt;=4-fold increase in post-booster titer as determined by PRNT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTs of Antibodies Against Each Dengue Virus Serotype Following the Third CYD Dengue Vaccine Injection Received in Study CYD13/CYD30, and Before Booster Injection With Either CYD Dengue Vaccine or Placebo</measure>
    <time_frame>28 days post-dose 3 in CYD13 or CYD30 and pre-booster injection (Day 0) in CYD64</time_frame>
    <description>GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) were assessed using the PRNT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTRs of Antibodies Against Each Dengue Virus Serotype Following the Third CYD Dengue Vaccine Injection Received in Study CYD13/CYD30, and Before Booster Injection With Either CYD Dengue Vaccine or Placebo</measure>
    <time_frame>28 days post-dose 3 in CYD13 or CYD30 and pre-booster injection (Day 0) in CYD64</time_frame>
    <description>GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) were assessed using the PRNT. GMTRs were calculated as the ratio of GMTs pre-booster injection and post-dose injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following the Third CYD Dengue Vaccine Injection Received in Study CYD13/CYD30, and Following Booster Injection With Either CYD Dengue Vaccine or Placebo</measure>
    <time_frame>28 days post-dose 3 in CYD13 or CYD30 and 28 days post-booster injection in CYD64</time_frame>
    <description>Seropositivity against each dengue virus serotype were measured using dengue PRNT. Seropositive participants were defined as the participants with neutralizing antibody titers &gt;=10 (1/dilution).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTs of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With Either CYD Dengue Vaccine or Placebo</measure>
    <time_frame>6 months,12 months, and 24 months post-booster injection in CYD64</time_frame>
    <description>GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) following booster injection were assessed using PRNT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTRs of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With Either CYD Dengue Vaccine or Placebo</measure>
    <time_frame>Pre-booster injection (Day 0), 6 months, 12 months, and 24 months post-booster injection in CYD64</time_frame>
    <description>GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) following booster injection were assessed using PRNT. GMTRs were calculated as the ratio of GMTs post-booster injection and pre-booster injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Booster Injection With Either CYD Dengue Vaccine or Placebo</measure>
    <time_frame>6 months,12 months, and 24 months post-booster injection in CYD64</time_frame>
    <description>Seropositivity against each dengue virus serotype were measured using dengue PRNT. Seropositive participants were defined as the participants with neutralizing antibody titers &gt;=10 (1/dilution).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Booster Injection With Either CYD Dengue Vaccine or Placebo</measure>
    <time_frame>Within 7 days after booster injection</time_frame>
    <description>Solicited injection site reactions: Pain, Erythema, and Swelling. Grade 3 reactions: Pain: significant; prevents daily activity; Erythema and Swelling: &gt;100 millimeters (mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Booster Injection With Either CYD Dengue Vaccine or Placebo</measure>
    <time_frame>Within 14 days after booster injection</time_frame>
    <description>Solicited systemic reactions: Fever, Headache, Malaise, Myalgia, and Asthenia. Grade 3 reactions: Fever: &gt;=39°C; Headache, Malaise, Myalgia, and Asthenia: significant, prevents daily activity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">251</enrollment>
  <condition>Dengue Fever</condition>
  <condition>Dengue Hemorrhagic Fever</condition>
  <arm_group>
    <arm_group_label>CYD Dengue Vaccine Booster Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CYD Dengue Vaccine (5-dose formulation)</intervention_name>
    <description>0.5 mL, Subcutaneous</description>
    <arm_group_label>CYD Dengue Vaccine Booster Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo, NaCl 0.9%</intervention_name>
    <description>0.5 mL, Subcutaneous</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Had been identified as a potential participant by the Sponsor and is included in the
             list provided to the Investigator (i.e., aged 9 to 16 years on the day of first
             vaccination of CYD dengue vaccine in CYD13/CYD30 and has a post-dose 3 serum sample
             available [at least 400 microliters of serum]).

          -  Participants were in good health, based on medical history and physical examination.

          -  Assent form or informed consent form (ICF) had been signed and dated by the
             participant (based on local regulations), and ICF had been signed and dated by the
             parent(s) or another legally acceptable representative (and by an independent witness
             if required by local regulations).

          -  Participant and parent(s)/legally acceptable representative(s) attended all scheduled
             visits and complied with all trial procedures.

        Exclusion Criteria:

          -  Participant who received any other dengue vaccination that was not part of the CYD13
             or CYD30 trials.

          -  Participant was pregnant, or lactating, or of childbearing potential (to be considered
             of non childbearing potential, a female must be pre-menarche or post-menopausal for at
             least 1 year, surgically sterile, or using an effective method of contraception or
             abstinence from at least 4 weeks prior to vaccination until at least 4 weeks after
             vaccination).

          -  Participation at the time of study enrollment (or in the 4 weeks preceding the trial
             vaccination) or planned participation during the present trial period in another
             clinical trial investigating a vaccine, drug, medical device, or medical procedure.

          -  Receipt of any vaccine in the 4 weeks preceding the trial vaccination or planned
             receipt of any vaccine in the 4 weeks following the trial vaccination.

          -  Receipt of immune globulins, blood or blood-derived products in the past 3 months.

          -  Known or suspected congenital or acquired immunodeficiency; or receipt of
             immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy,
             within the preceding 6 months; or long-term systemic corticosteroid therapy
             (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).

          -  Known systemic hypersensitivity to any of the vaccine components, or history of a
             life-threatening reaction to the vaccines used in the trial or to a vaccine containing
             any of the same substances.

          -  Chronic illness that, in the opinion of the Investigator, was at a stage where it
             might interfere with trial conduct or completion.

          -  Receipt of blood or blood-derived products in the past 3 months, which might interfere
             with assessment of the immune response.

          -  Deprived of freedom by an administrative or court order, or in an emergency setting,
             or hospitalized involuntarily.

          -  Current alcohol abuse or drug addiction.

          -  Moderate or severe acute illness/infection (according to investigator judgment) on the
             day of vaccination or febrile illness (temperature &gt;= 38.0°C). A prospective
             participant should not be included in the study until the condition had resolved or
             the febrile event had subsided.

          -  Identified as an Investigator or employee of the Investigator or study center with
             direct involvement in the proposed study, or identified as an immediate family member
             (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with
             direct involvement in the proposed study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 001</name>
      <address>
        <city>Vitoria</city>
        <zip>29040-091</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 002</name>
      <address>
        <city>Bucaramanga</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 003</name>
      <address>
        <city>Tegucigalpa</city>
        <country>Honduras</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 004</name>
      <address>
        <city>Temixco</city>
        <zip>62587</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 005</name>
      <address>
        <city>Carolina</city>
        <zip>984</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Honduras</country>
    <country>Mexico</country>
    <country>Puerto Rico</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>December 3, 2015</study_first_submitted>
  <study_first_submitted_qc>December 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2015</study_first_posted>
  <results_first_submitted>May 24, 2019</results_first_submitted>
  <results_first_submitted_qc>May 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2019</results_first_posted>
  <disposition_first_submitted>November 16, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>November 16, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 20, 2017</disposition_first_posted>
  <last_update_submitted>October 18, 2019</last_update_submitted>
  <last_update_submitted_qc>October 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dengue Fever</keyword>
  <keyword>Dengue virus</keyword>
  <keyword>Dengue Hemorrhagic Fever</keyword>
  <keyword>CYD Dengue Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
    <mesh_term>Hemorrhagic Fevers, Viral</mesh_term>
    <mesh_term>Severe Dengue</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to participant level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were enrolled from 14 April 2016 to 19 October 2016 at 5 sites, one each in Brazil, Colombia, Honduras, Mexico, and Puerto Rico.</recruitment_details>
      <pre_assignment_details>A total of 251 participants who received 3 doses of CYD dengue vaccine in previous studies CYD13 (NCT00993447) and CYD30 (NCT01187433) were enrolled and randomized in this study (CYD64).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CYD Dengue Vaccine Booster Group</title>
          <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64).</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="187"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="171"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Non compliance with protocol</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Serious adverse event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis was performed on all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>CYD Dengue Vaccine Booster Group</title>
          <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64).</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="187"/>
            <count group_id="B2" value="64"/>
            <count group_id="B3" value="251"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="169"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.2" spread="2.14"/>
                    <measurement group_id="B2" value="19.0" spread="1.99"/>
                    <measurement group_id="B3" value="19.1" spread="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With CYD Dengue Vaccine in CYD64 Compared to Third CYD Dengue Vaccine Received in CYD13/CYD30: CYD Dengue Vaccine Booster Group</title>
        <description>Geometric Mean Titers (GMTs) of antibodies against each of the 4 dengue virus serotype (parental strains) were assessed using the plaque reduction neutralization test (PRNT).</description>
        <time_frame>28 days post-dose 3 in CYD13 or CYD30 and 28 days post-booster injection in CYD64</time_frame>
        <population>Analysis was performed on Per-Protocol Analysis Set which included all participants who had no protocol deviations from the present study (CYD64). Here, ‘number analyzed’ = participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Booster Group:Post Dose 3 in CYD13 or CYD30</title>
            <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30) were included in this study (CYD64).</description>
          </group>
          <group group_id="O2">
            <title>CYD Dengue Vaccine Booster Group: Post Booster Dose in CYD64</title>
            <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With CYD Dengue Vaccine in CYD64 Compared to Third CYD Dengue Vaccine Received in CYD13/CYD30: CYD Dengue Vaccine Booster Group</title>
          <description>Geometric Mean Titers (GMTs) of antibodies against each of the 4 dengue virus serotype (parental strains) were assessed using the plaque reduction neutralization test (PRNT).</description>
          <population>Analysis was performed on Per-Protocol Analysis Set which included all participants who had no protocol deviations from the present study (CYD64). Here, ‘number analyzed’ = participants with available data for each specified category.</population>
          <units>titers (1/dilution)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dengue Virus Serotype 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="316" lower_limit="233" upper_limit="428"/>
                    <measurement group_id="O2" value="560" lower_limit="421" upper_limit="744"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="356" lower_limit="275" upper_limit="462"/>
                    <measurement group_id="O2" value="657" lower_limit="520" upper_limit="830"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="640" lower_limit="516" upper_limit="794"/>
                    <measurement group_id="O2" value="671" lower_limit="535" upper_limit="843"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243" lower_limit="195" upper_limit="303"/>
                    <measurement group_id="O2" value="344" lower_limit="279" upper_limit="424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dengue Virus Serotype 1</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The overall non-inferiority of the booster dose was to be demonstrated if the lower limit of the two-sided 95 percent (%) Confidence Interval (CI) of the Geometric mean of titer ratios (GMTRs) (booster vs post-dose 3) was greater than (&gt;) 1/2 for each serotype.</non_inferiority_desc>
            <param_type>Geometric mean of titer ratio</param_type>
            <param_value>1.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.33</ci_lower_limit>
            <ci_upper_limit>2.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dengue Virus Serotype 2</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The overall non-inferiority of the booster dose was to be demonstrated if the lower limit of the two-sided 95% CI of the GMTRs (booster vs post-dose 3) was &gt;1/2 for each serotype.</non_inferiority_desc>
            <param_type>Geometric mean of titer ratio</param_type>
            <param_value>1.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.43</ci_lower_limit>
            <ci_upper_limit>2.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dengue Virus Serotype 3</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The overall non-inferiority of the booster dose was to be demonstrated if the lower limit of the two-sided 95% CI of the GMTRs (booster vs post-dose 3) was &gt;1/2 for each serotype.</non_inferiority_desc>
            <param_type>Geometric mean of titer ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.841</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dengue Virus Serotype 4</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The overall non-inferiority of the booster dose was to be demonstrated if the lower limit of the two-sided 95% CI of the GMTRs (booster vs post-dose 3) was &gt;1/2 for each serotype.</non_inferiority_desc>
            <param_type>Geometric mean of titer ratio</param_type>
            <param_value>1.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>1.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMTs of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With CYD Dengue Vaccine in CYD64 Compared to Third CYD Dengue Vaccine Received in CYD13/CYD30: CYD Dengue Vaccine Booster Group</title>
        <description>GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) following booster injection were assessed using PRNT.</description>
        <time_frame>28 days post-dose 3 in CYD13 or CYD30 and 28 days post-booster injection in CYD64</time_frame>
        <population>Analysis was performed on Full analysis set which included all participants who received either CYD Dengue Vaccine or placebo and had blood sample drawn and valid post-injection serology results. Here, ‘number analyzed’ = participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Booster Group:Post Dose 3 in CYD13 or CYD30</title>
            <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30) were included in this study (CYD64).</description>
          </group>
          <group group_id="O2">
            <title>CYD Dengue Vaccine Booster Group: Post Booster Dose in CYD64</title>
            <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64).</description>
          </group>
        </group_list>
        <measure>
          <title>GMTs of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With CYD Dengue Vaccine in CYD64 Compared to Third CYD Dengue Vaccine Received in CYD13/CYD30: CYD Dengue Vaccine Booster Group</title>
          <description>GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) following booster injection were assessed using PRNT.</description>
          <population>Analysis was performed on Full analysis set which included all participants who received either CYD Dengue Vaccine or placebo and had blood sample drawn and valid post-injection serology results. Here, ‘number analyzed’ = participants with available data for each specified category.</population>
          <units>titers (1/dilution)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dengue Virus Serotype 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="183"/>
                    <count group_id="O2" value="184"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304" lower_limit="225" upper_limit="409"/>
                    <measurement group_id="O2" value="538" lower_limit="406" upper_limit="714"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                    <count group_id="O2" value="184"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338" lower_limit="261" upper_limit="436"/>
                    <measurement group_id="O2" value="648" lower_limit="515" upper_limit="817"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                    <count group_id="O2" value="184"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="617" lower_limit="499" upper_limit="762"/>
                    <measurement group_id="O2" value="660" lower_limit="528" upper_limit="827"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="183"/>
                    <count group_id="O2" value="184"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241" lower_limit="195" upper_limit="298"/>
                    <measurement group_id="O2" value="341" lower_limit="278" upper_limit="418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dengue Virus Serotype 1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The superiority was to be demonstrated if the lower limit of the two-sided 95% CI for the ratio was &gt;1.</non_inferiority_desc>
            <param_type>Geometric mean of titer ratio</param_type>
            <param_value>1.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.34</ci_lower_limit>
            <ci_upper_limit>2.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dengue Virus Serotype 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The superiority was to be demonstrated if the lower limit of the two-sided 95% CI for the ratio was &gt;1.</non_inferiority_desc>
            <param_type>Geometric mean of titer ratio</param_type>
            <param_value>1.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.49</ci_lower_limit>
            <ci_upper_limit>2.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dengue Virus Serotype 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The superiority was to be demonstrated if the lower limit of the two-sided 95% CI for the ratio was &gt;1.</non_inferiority_desc>
            <param_type>Geometric mean of titer ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.860</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dengue Virus Serotype 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The superiority was to be demonstrated if the lower limit of the two-sided 95% CI for the ratio was &gt;1.</non_inferiority_desc>
            <param_type>Geometric mean of titer ratio</param_type>
            <param_value>1.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>1.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMTs of Antibodies Against Each Dengue Virus Serotype Before And Following Booster Injection (Inj.) With Either CYD Dengue Vaccine or Placebo</title>
        <description>GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) following booster injection were assessed using PRNT.</description>
        <time_frame>Pre-booster injection (Day 0) and 28 days post-booster injection</time_frame>
        <population>Analysis was performed on Per-Protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Booster Group</title>
            <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64).</description>
          </group>
        </group_list>
        <measure>
          <title>GMTs of Antibodies Against Each Dengue Virus Serotype Before And Following Booster Injection (Inj.) With Either CYD Dengue Vaccine or Placebo</title>
          <description>GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) following booster injection were assessed using PRNT.</description>
          <population>Analysis was performed on Per-Protocol Analysis Set.</population>
          <units>titers (1/dilution)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dengue Virus Serotype 1: Pre-booster Inj.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="325" lower_limit="233" upper_limit="452"/>
                    <measurement group_id="O2" value="349" lower_limit="201" upper_limit="607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 1: 28 days Post-booster Inj.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="560" lower_limit="421" upper_limit="744"/>
                    <measurement group_id="O2" value="297" lower_limit="162" upper_limit="547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 2: Pre-booster Inj.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="360" lower_limit="267" upper_limit="484"/>
                    <measurement group_id="O2" value="323" lower_limit="195" upper_limit="535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 2: 28 days Post-booster Inj.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="657" lower_limit="520" upper_limit="830"/>
                    <measurement group_id="O2" value="354" lower_limit="205" upper_limit="610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 3: Pre-booster Inj.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="357" lower_limit="269" upper_limit="472"/>
                    <measurement group_id="O2" value="442" lower_limit="270" upper_limit="724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 3: 28 days Post-booster Inj.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="671" lower_limit="535" upper_limit="843"/>
                    <measurement group_id="O2" value="432" lower_limit="266" upper_limit="700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 4: Pre-booster Inj.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162" lower_limit="134" upper_limit="195"/>
                    <measurement group_id="O2" value="161" lower_limit="108" upper_limit="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 4: 28 days Post-booster Inj.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="344" lower_limit="279" upper_limit="424"/>
                    <measurement group_id="O2" value="161" lower_limit="110" upper_limit="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMTRs of Antibodies Against Each Dengue Virus Serotype Before and Following Booster Injection With Either CYD Dengue Vaccine or Placebo</title>
        <description>GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) following booster injection were assessed using PRNT. GMTRs were calculated as the ratio of GMTs post-booster injection and pre-booster injection.</description>
        <time_frame>Pre-booster injection (Day 0) and 28 days post-booster injection</time_frame>
        <population>Analysis was performed on Per-Protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Booster Group</title>
            <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64).</description>
          </group>
        </group_list>
        <measure>
          <title>GMTRs of Antibodies Against Each Dengue Virus Serotype Before and Following Booster Injection With Either CYD Dengue Vaccine or Placebo</title>
          <description>GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) following booster injection were assessed using PRNT. GMTRs were calculated as the ratio of GMTs post-booster injection and pre-booster injection.</description>
          <population>Analysis was performed on Per-Protocol Analysis Set.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dengue Virus Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.59" lower_limit="1.33" upper_limit="1.90"/>
                    <measurement group_id="O2" value="0.798" lower_limit="0.623" upper_limit="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" lower_limit="1.43" upper_limit="2.03"/>
                    <measurement group_id="O2" value="1.03" lower_limit="0.754" upper_limit="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78" lower_limit="1.47" upper_limit="2.16"/>
                    <measurement group_id="O2" value="0.946" lower_limit="0.749" upper_limit="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.09" lower_limit="1.65" upper_limit="2.63"/>
                    <measurement group_id="O2" value="0.946" lower_limit="0.777" upper_limit="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Before and Following Booster Injection With Either CYD Dengue Vaccine or Placebo</title>
        <description>Seropositivity against each dengue virus serotype were measured using dengue PRNT. Seropositive participants were defined as the participants with neutralizing antibody titers greater than or equal to (&gt;=)10 (1/dilution).</description>
        <time_frame>Pre-booster injection (Day 0) and 28 days post-booster injection</time_frame>
        <population>Analysis was performed on Per-Protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Booster Group</title>
            <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Before and Following Booster Injection With Either CYD Dengue Vaccine or Placebo</title>
          <description>Seropositivity against each dengue virus serotype were measured using dengue PRNT. Seropositive participants were defined as the participants with neutralizing antibody titers greater than or equal to (&gt;=)10 (1/dilution).</description>
          <population>Analysis was performed on Per-Protocol Analysis Set.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dengue Virus Serotype 1: Pre-booster Inj.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.1"/>
                    <measurement group_id="O2" value="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 1: 28 days Post-booster Inj.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0"/>
                    <measurement group_id="O2" value="84.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 2: Pre-booster Inj.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.8"/>
                    <measurement group_id="O2" value="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 2: 28 days Post-booster Inj.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9"/>
                    <measurement group_id="O2" value="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 3: Pre-booster Inj.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.1"/>
                    <measurement group_id="O2" value="95.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 3: 28 days Post-booster Inj.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4"/>
                    <measurement group_id="O2" value="95.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 4: Pre-booster Inj.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.2"/>
                    <measurement group_id="O2" value="92.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 4: 28 days Post-booster Inj.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="93.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion Against Each Dengue Virus Serotype Following Booster Injection With Either CYD Dengue Vaccine or Placebo</title>
        <description>Seroconversion for each serotype was defined as the percentage of participants with either a pre-booster titer &lt;10 (1/dilution) and a post-booster titer &gt;=40 (1/dilution), or a pre-booster titer &gt;=10 (1/dilution) and a &gt;=4-fold increase in post-booster titer as determined by PRNT.</description>
        <time_frame>28 days post-booster injection</time_frame>
        <population>Analysis was performed on Full analysis set. Here, ‘number analyzed’ = participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Booster Group</title>
            <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion Against Each Dengue Virus Serotype Following Booster Injection With Either CYD Dengue Vaccine or Placebo</title>
          <description>Seroconversion for each serotype was defined as the percentage of participants with either a pre-booster titer &lt;10 (1/dilution) and a post-booster titer &gt;=40 (1/dilution), or a pre-booster titer &gt;=10 (1/dilution) and a &gt;=4-fold increase in post-booster titer as determined by PRNT.</description>
          <population>Analysis was performed on Full analysis set. Here, ‘number analyzed’ = participants with available data for each specified category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dengue Virus Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9"/>
                    <measurement group_id="O2" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1"/>
                    <measurement group_id="O2" value="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2"/>
                    <measurement group_id="O2" value="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7"/>
                    <measurement group_id="O2" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMTs of Antibodies Against Each Dengue Virus Serotype Following the Third CYD Dengue Vaccine Injection Received in Study CYD13/CYD30, and Before Booster Injection With Either CYD Dengue Vaccine or Placebo</title>
        <description>GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) were assessed using the PRNT.</description>
        <time_frame>28 days post-dose 3 in CYD13 or CYD30 and pre-booster injection (Day 0) in CYD64</time_frame>
        <population>Analysis was performed on Per-Protocol Analysis Set. Here, ‘number analyzed’ = participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Booster Group</title>
            <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64).</description>
          </group>
        </group_list>
        <measure>
          <title>GMTs of Antibodies Against Each Dengue Virus Serotype Following the Third CYD Dengue Vaccine Injection Received in Study CYD13/CYD30, and Before Booster Injection With Either CYD Dengue Vaccine or Placebo</title>
          <description>GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) were assessed using the PRNT.</description>
          <population>Analysis was performed on Per-Protocol Analysis Set. Here, ‘number analyzed’ = participants with available data for each specified category.</population>
          <units>titers (1/dilution)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dengue Virus Serotype 1: 28 days Post-dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="316" lower_limit="233" upper_limit="428"/>
                    <measurement group_id="O2" value="232" lower_limit="142" upper_limit="381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 1: Pre-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="325" lower_limit="233" upper_limit="452"/>
                    <measurement group_id="O2" value="349" lower_limit="201" upper_limit="607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 2: 28 days Post-dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="356" lower_limit="275" upper_limit="462"/>
                    <measurement group_id="O2" value="303" lower_limit="210" upper_limit="438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 2: Pre-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="360" lower_limit="267" upper_limit="484"/>
                    <measurement group_id="O2" value="323" lower_limit="195" upper_limit="535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 3: 28 days Post-dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="640" lower_limit="516" upper_limit="794"/>
                    <measurement group_id="O2" value="541" lower_limit="372" upper_limit="785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 3: Pre-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="357" lower_limit="269" upper_limit="472"/>
                    <measurement group_id="O2" value="442" lower_limit="270" upper_limit="724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 4: 28 days Post-dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243" lower_limit="195" upper_limit="303"/>
                    <measurement group_id="O2" value="255" lower_limit="192" upper_limit="340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 4: Pre-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162" lower_limit="134" upper_limit="195"/>
                    <measurement group_id="O2" value="161" lower_limit="108" upper_limit="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMTRs of Antibodies Against Each Dengue Virus Serotype Following the Third CYD Dengue Vaccine Injection Received in Study CYD13/CYD30, and Before Booster Injection With Either CYD Dengue Vaccine or Placebo</title>
        <description>GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) were assessed using the PRNT. GMTRs were calculated as the ratio of GMTs pre-booster injection and post-dose injection.</description>
        <time_frame>28 days post-dose 3 in CYD13 or CYD30 and pre-booster injection (Day 0) in CYD64</time_frame>
        <population>Analysis was performed on Per-Protocol Analysis Set. Here, ‘number analyzed’=participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Booster Group</title>
            <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64).</description>
          </group>
        </group_list>
        <measure>
          <title>GMTRs of Antibodies Against Each Dengue Virus Serotype Following the Third CYD Dengue Vaccine Injection Received in Study CYD13/CYD30, and Before Booster Injection With Either CYD Dengue Vaccine or Placebo</title>
          <description>GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) were assessed using the PRNT. GMTRs were calculated as the ratio of GMTs pre-booster injection and post-dose injection.</description>
          <population>Analysis was performed on Per-Protocol Analysis Set. Here, ‘number analyzed’=participants with available data for each specified category.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dengue Virus Serotype 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.952" lower_limit="0.765" upper_limit="1.18"/>
                    <measurement group_id="O2" value="1.41" lower_limit="0.927" upper_limit="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.986" lower_limit="0.778" upper_limit="1.25"/>
                    <measurement group_id="O2" value="1.04" lower_limit="0.662" upper_limit="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.536" lower_limit="0.440" upper_limit="0.654"/>
                    <measurement group_id="O2" value="0.818" lower_limit="0.574" upper_limit="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.618" lower_limit="0.497" upper_limit="0.770"/>
                    <measurement group_id="O2" value="0.613" lower_limit="0.427" upper_limit="0.881"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following the Third CYD Dengue Vaccine Injection Received in Study CYD13/CYD30, and Following Booster Injection With Either CYD Dengue Vaccine or Placebo</title>
        <description>Seropositivity against each dengue virus serotype were measured using dengue PRNT. Seropositive participants were defined as the participants with neutralizing antibody titers &gt;=10 (1/dilution).</description>
        <time_frame>28 days post-dose 3 in CYD13 or CYD30 and 28 days post-booster injection in CYD64</time_frame>
        <population>Analysis was performed on Per-Protocol Analysis Set. Here, ‘number analyzed’ = participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Booster Group</title>
            <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following the Third CYD Dengue Vaccine Injection Received in Study CYD13/CYD30, and Following Booster Injection With Either CYD Dengue Vaccine or Placebo</title>
          <description>Seropositivity against each dengue virus serotype were measured using dengue PRNT. Seropositive participants were defined as the participants with neutralizing antibody titers &gt;=10 (1/dilution).</description>
          <population>Analysis was performed on Per-Protocol Analysis Set. Here, ‘number analyzed’ = participants with available data for each specified category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dengue Virus Serotype 1: 28 days Post-dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9"/>
                    <measurement group_id="O2" value="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 1: 28 days Post-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0"/>
                    <measurement group_id="O2" value="84.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 2: 28 days Post-dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.4"/>
                    <measurement group_id="O2" value="96.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 2: 28 days Post-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9"/>
                    <measurement group_id="O2" value="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 3: 28 days Post-dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 3: 28 days Post-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4"/>
                    <measurement group_id="O2" value="95.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 4: 28 days Post-dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.0"/>
                    <measurement group_id="O2" value="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 4: 28 days Post-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="93.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMTs of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With Either CYD Dengue Vaccine or Placebo</title>
        <description>GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) following booster injection were assessed using PRNT.</description>
        <time_frame>6 months,12 months, and 24 months post-booster injection in CYD64</time_frame>
        <population>Analysis was performed on Per-Protocol Analysis Set. Here, 'number analyzed' = participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Booster Group</title>
            <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64).</description>
          </group>
        </group_list>
        <measure>
          <title>GMTs of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With Either CYD Dengue Vaccine or Placebo</title>
          <description>GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) following booster injection were assessed using PRNT.</description>
          <population>Analysis was performed on Per-Protocol Analysis Set. Here, 'number analyzed' = participants with available data for each specified category.</population>
          <units>titers (1/dilution)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dengue Virus Serotype 1:6 months Post-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270" lower_limit="205" upper_limit="356"/>
                    <measurement group_id="O2" value="192" lower_limit="111" upper_limit="329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype1:12 months Post-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270" lower_limit="205" upper_limit="356"/>
                    <measurement group_id="O2" value="185" lower_limit="112" upper_limit="304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype1:24 months Post-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241" lower_limit="180" upper_limit="323"/>
                    <measurement group_id="O2" value="182" lower_limit="112" upper_limit="297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 2:6 months Post-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="442" lower_limit="358" upper_limit="546"/>
                    <measurement group_id="O2" value="335" lower_limit="217" upper_limit="515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype2:12 months Post-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269" lower_limit="217" upper_limit="335"/>
                    <measurement group_id="O2" value="225" lower_limit="152" upper_limit="334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype2:24 months Post-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246" lower_limit="192" upper_limit="315"/>
                    <measurement group_id="O2" value="187" lower_limit="126" upper_limit="279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 3:6 months Post-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="503" lower_limit="397" upper_limit="636"/>
                    <measurement group_id="O2" value="447" lower_limit="285" upper_limit="701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype3:12 months Post-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="303" lower_limit="242" upper_limit="379"/>
                    <measurement group_id="O2" value="328" lower_limit="219" upper_limit="491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype3:24 months Post-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="341" lower_limit="275" upper_limit="423"/>
                    <measurement group_id="O2" value="309" lower_limit="194" upper_limit="492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 4:6 months Post-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233" lower_limit="198" upper_limit="273"/>
                    <measurement group_id="O2" value="156" lower_limit="115" upper_limit="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype4:12 months Post-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169" lower_limit="144" upper_limit="199"/>
                    <measurement group_id="O2" value="127" lower_limit="96.3" upper_limit="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype4:24 months Post-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150" lower_limit="129" upper_limit="174"/>
                    <measurement group_id="O2" value="114" lower_limit="85.2" upper_limit="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMTRs of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With Either CYD Dengue Vaccine or Placebo</title>
        <description>GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) following booster injection were assessed using PRNT. GMTRs were calculated as the ratio of GMTs post-booster injection and pre-booster injection.</description>
        <time_frame>Pre-booster injection (Day 0), 6 months, 12 months, and 24 months post-booster injection in CYD64</time_frame>
        <population>Analysis was performed on Per-Protocol Analysis Set. Here, 'number analyzed' = participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Booster Group</title>
            <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64).</description>
          </group>
        </group_list>
        <measure>
          <title>GMTRs of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With Either CYD Dengue Vaccine or Placebo</title>
          <description>GMTs of antibodies against each of the 4 dengue virus serotype (parental strains) following booster injection were assessed using PRNT. GMTRs were calculated as the ratio of GMTs post-booster injection and pre-booster injection.</description>
          <population>Analysis was performed on Per-Protocol Analysis Set. Here, 'number analyzed' = participants with available data for each specified category.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dengue Virus Serotype 1: Month 6/Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.763" lower_limit="0.643" upper_limit="0.904"/>
                    <measurement group_id="O2" value="0.502" lower_limit="0.364" upper_limit="0.693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 1: Month 12/Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.722" lower_limit="0.607" upper_limit="0.859"/>
                    <measurement group_id="O2" value="0.483" lower_limit="0.366" upper_limit="0.638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 1: Month 24/Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.642" lower_limit="0.532" upper_limit="0.774"/>
                    <measurement group_id="O2" value="0.509" lower_limit="0.382" upper_limit="0.678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 2: Month 6/Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" lower_limit="0.922" upper_limit="1.40"/>
                    <measurement group_id="O2" value="0.998" lower_limit="0.716" upper_limit="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 2: Month 12/Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.651" lower_limit="0.539" upper_limit="0.786"/>
                    <measurement group_id="O2" value="0.630" lower_limit="0.460" upper_limit="0.863"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 2: Month 24/Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.579" lower_limit="0.473" upper_limit="0.709"/>
                    <measurement group_id="O2" value="0.548" lower_limit="0.373" upper_limit="0.806"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 3: Month 6/Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" lower_limit="1.09" upper_limit="1.65"/>
                    <measurement group_id="O2" value="0.957" lower_limit="0.701" upper_limit="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 3: Month 12/Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.786" lower_limit="0.652" upper_limit="0.947"/>
                    <measurement group_id="O2" value="0.667" lower_limit="0.505" upper_limit="0.883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 3: Month 24/Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.878" lower_limit="0.749" upper_limit="1.03"/>
                    <measurement group_id="O2" value="0.682" lower_limit="0.523" upper_limit="0.890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 4: Month 6/Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" lower_limit="1.17" upper_limit="1.72"/>
                    <measurement group_id="O2" value="0.912" lower_limit="0.691" upper_limit="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 4: Month 12/Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" lower_limit="0.846" upper_limit="1.22"/>
                    <measurement group_id="O2" value="0.709" lower_limit="0.553" upper_limit="0.909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 4: Month 24/Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.890" lower_limit="0.753" upper_limit="1.05"/>
                    <measurement group_id="O2" value="0.684" lower_limit="0.534" upper_limit="0.877"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Booster Injection With Either CYD Dengue Vaccine or Placebo</title>
        <description>Seropositivity against each dengue virus serotype were measured using dengue PRNT. Seropositive participants were defined as the participants with neutralizing antibody titers &gt;=10 (1/dilution).</description>
        <time_frame>6 months,12 months, and 24 months post-booster injection in CYD64</time_frame>
        <population>Analysis was performed on Per-Protocol Analysis Set. Here, 'number analyzed' = participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Booster Group</title>
            <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Booster Injection With Either CYD Dengue Vaccine or Placebo</title>
          <description>Seropositivity against each dengue virus serotype were measured using dengue PRNT. Seropositive participants were defined as the participants with neutralizing antibody titers &gt;=10 (1/dilution).</description>
          <population>Analysis was performed on Per-Protocol Analysis Set. Here, 'number analyzed' = participants with available data for each specified category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dengue Virus Serotype 1:6 months Post-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4"/>
                    <measurement group_id="O2" value="85.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype1:12 months Post-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9"/>
                    <measurement group_id="O2" value="88.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype1:24 months Post-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.2"/>
                    <measurement group_id="O2" value="89.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 2:6 months Post-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9"/>
                    <measurement group_id="O2" value="92.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype2:12 months Post-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.5"/>
                    <measurement group_id="O2" value="91.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype2:24 months Post-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3"/>
                    <measurement group_id="O2" value="91.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 3:6 months Post-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7"/>
                    <measurement group_id="O2" value="95.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype3:12 months Post-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1"/>
                    <measurement group_id="O2" value="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype3:24 months Post-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4"/>
                    <measurement group_id="O2" value="94.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 4:6 months Post-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9"/>
                    <measurement group_id="O2" value="95.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype4:12 months Post-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6"/>
                    <measurement group_id="O2" value="95.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype4:24 months Post-booster Inj.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8"/>
                    <measurement group_id="O2" value="94.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Booster Injection With Either CYD Dengue Vaccine or Placebo</title>
        <description>Solicited injection site reactions: Pain, Erythema, and Swelling. Grade 3 reactions: Pain: significant; prevents daily activity; Erythema and Swelling: &gt;100 millimeters (mm).</description>
        <time_frame>Within 7 days after booster injection</time_frame>
        <population>Analysis was performed on Safety Analysis Set which included all participants who received either CYD dengue vaccine or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Booster Group</title>
            <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Booster Injection With Either CYD Dengue Vaccine or Placebo</title>
          <description>Solicited injection site reactions: Pain, Erythema, and Swelling. Grade 3 reactions: Pain: significant; prevents daily activity; Erythema and Swelling: &gt;100 millimeters (mm).</description>
          <population>Analysis was performed on Safety Analysis Set which included all participants who received either CYD dengue vaccine or placebo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection-site Pain: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Pain: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Erythema: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Erythema: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Swelling: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Swelling: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Booster Injection With Either CYD Dengue Vaccine or Placebo</title>
        <description>Solicited systemic reactions: Fever, Headache, Malaise, Myalgia, and Asthenia. Grade 3 reactions: Fever: &gt;=39°C; Headache, Malaise, Myalgia, and Asthenia: significant, prevents daily activity.</description>
        <time_frame>Within 14 days after booster injection</time_frame>
        <population>Analysis was performed on Safety Analysis Set. Here, ‘number analyzed’ = participants with available data for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Booster Group</title>
            <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Booster Injection With Either CYD Dengue Vaccine or Placebo</title>
          <description>Solicited systemic reactions: Fever, Headache, Malaise, Myalgia, and Asthenia. Grade 3 reactions: Fever: &gt;=39°C; Headache, Malaise, Myalgia, and Asthenia: significant, prevents daily activity.</description>
          <population>Analysis was performed on Safety Analysis Set. Here, ‘number analyzed’ = participants with available data for specified category.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: Any Grade</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="179"/>
                    <count group_id="O2" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="179"/>
                    <count group_id="O2" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Any Grade</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise: Any Grade</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia: Any Grade</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthenia: Any Grade</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthenia: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event (AE) data was collected from Day 0 (post-vaccination) up to 28 days post-booster injection. Solicited Reaction (SR) data was collected within 7 and 14 days after vaccination. Serious adverse event (SAE) data was collected throughout the study (up to 24 months after last vaccination).</time_frame>
      <desc>Analysis was performed on Safety Analysis Set. A SR was an AE that was prelisted (i.e., solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction). An unsolicited AE was an observed AE that did not fulfill the conditions prelisted (i.e., solicited) in the eCRF in terms of symptom and/or onset post-vaccination.</desc>
      <group_list>
        <group group_id="E1">
          <title>CYD Dengue Vaccine Booster Group</title>
          <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64).</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Gun Shot Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Intentional Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Toxicity To Various Agents</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Abortion Spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Ectopic Pregnancy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Pre-Eclampsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed Suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion Induced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="52" subjects_affected="52" subjects_at_risk="187"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" events="46" subjects_affected="46" subjects_at_risk="187"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="48" subjects_affected="47" subjects_at_risk="187"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="187"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="61" subjects_affected="60" subjects_at_risk="187"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="90" subjects_affected="88" subjects_at_risk="187"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur</organization>
      <phone>800-633-1610 ext ext 1#</phone>
      <email>Contact-US@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

